{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T20:43:03Z","timestamp":1769978583349,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,3,8]],"date-time":"2009-03-08T00:00:00Z","timestamp":1236470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite durable responses to imatinib in chronic myeloid leukaemia (CML), mutations in Bcr\u2010Abl kinase domain (KD) are known to induce imatinib resistance and cause poor clinical outcome. We characterized Bcr\u2010Abl KD mutations in 137 Korean CML patients with imatinib resistance (<jats:italic>n<\/jats:italic>\u2009=\u2009111) or intolerance (<jats:italic>n<\/jats:italic>\u2009=\u200926) using allele specific oligonucleotide polymerase chain reaction (PCR) and direct sequencing. Seventy (51%) patients harboured 81 mutations of 20 different types with increasing prevalence in advanced phase. Nine (13%) patients had multiple mutations. No mutation was found in intolerant patients. T315I was the most common mutation and P\u2010loop was the hottest spot in Bcr\u2010Abl KD. Patients harbouring P\u2010loop mutation, T315I, or multiple mutations showed poor overall survival and progression free survival compared with patients harbouring other mutations. Survival analysis according to disease phase of mutation being detected and type of mutations provided correlation between P\u2010loop or T315I mutation and poor overall survival in blast crisis, but not in accelerated phase (AP) or chronic phase (CP), indicating poor clinical outcome of particular mutations depends on disease phase. CML patients with imatinib resistance showed high rate (63%) of mutations in Bcr\u2010Abl KD and therefore CML patients who do not respond to imatinib should be the candidates for mutation screening as molecular monitoring. Copyright \u00a9 2009 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.894","type":"journal-article","created":{"date-parts":[[2009,3,9]],"date-time":"2009-03-09T01:30:17Z","timestamp":1236562217000},"page":"190-197","source":"Crossref","is-referenced-by-count":39,"title":["Analysis of Bcr\u2010Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P\u2010loop and T315I mutation is disease phase dependent"],"prefix":"10.1002","volume":"27","author":[{"given":"Soo\u2010Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong\u2010Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun\u2010Gyung","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se\u2010Eun","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan\u2010Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Il\u2010Young","family":"Kweon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa\u2010Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/306277a0"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(84)90077-1"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.10.3343"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00096-X"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.162140299"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5486.1938"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3472"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402741"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00190-9"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.531"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1036"},{"key":"e_1_2_1_18_2","first-page":"659","article-title":"Comparison of allele specific oligonucleotide\u2010polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib","volume":"9","author":"Kang HY","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_1_19_2","first-page":"235","article-title":"The role of serial BCR\u2010ABL transcript monitoring in predicting the emergence of BCR\u2010ABL kinase mutations in imatinib\u2010treated patients with chronic myeloid leukemia","volume":"91","author":"Wang L","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-004-4271-0"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1516"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404318"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3659"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404236"},{"key":"e_1_2_1_25_2","first-page":"4236","article-title":"Crystal structures of the kinase domain of c\u2010Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI\u2010571)","volume":"62","author":"Nagar B","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.10215"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.10173"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2896"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30890"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.894","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T01:45:09Z","timestamp":1699926309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,8]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1002\/hon.894"],"URL":"https:\/\/doi.org\/10.1002\/hon.894","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,8]]}}}